Multiple expression patterns of biopathological markers as possible predictors of response to adjuvant chemotherapy with high dose epirubicin and cyclophosphamide (HD EC) for high risk breast cancer

Claudio Botti(Catholic University of America), Marcella Mottolese, F. Sciarretta, S. Brenna, L. Trinca, Maria Benevolo(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Robert Cavaliere, Francesca Conti(Neuroscience Institute)

The Breast

October 1, 1997

10.1016/s0960-9776(97)90049-7

Cited by 0

Related Papers

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

|Annals of Oncology|2016|398

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

|Clinical Cancer Research|2019|240

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

|Journal of Clinical Oncology|2022|231

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

|The Lancet|2015|202

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.

|Journal of Clinical Oncology|1988|168